GMP on-site inspection of new AC Hib triple vaccine

According to the website of the State Food and Drug Administration (CFDA) on June 6, the AC Hib triple vaccine workshop of Beijing green bamboo, a wholly-owned subsidiary of Zhifei biology, conducted on-site GMP inspection this month, and the products are closer to the market AC Hib triple vaccine (full name: AC group meningococcal (combined) Haemophilus influenzae (combined) vaccine) is a new heavy-duty product approved by Zhifei biology in April this year It is waiting for the above workshop to be put into production after GMP certification At present, there is no domestic enterprise to produce the product It is reported that the certification workshop is the existing production line of Zhifei biology, and after passing the certification, it will produce AC Hib triple vaccine on a small scale The company's AC Hib triple vaccine industrialization project, which was invested and constructed with over raised funds of 360 million yuan, is planned to be completed by the end of 2015 In July 2016, the company applied for GMP certification After the project is completed, the capacity of AC Hib will reach 30 million doses / year The head of Zhifei biology once said that AC Hib triple vaccine is an upgraded product of Hib vaccine and AC group meningitis vaccine, which can prevent the related diseases caused by group A, group C meningococci and Haemophilus influenzae b at the same time, and can reduce the number of vaccinations The market price of the vaccine will be no less than 180 yuan / piece, and the market capacity is expected to be about 68 million pieces, with a high prospect The vaccine is a heavy-duty vaccine product that the company has high hopes for.